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Listeriolysin O (LLO) is an essential virulence factor for the gram-positive bacterium Listeria monocytogenes.
Our goal was to determine if altering the topology of LLO would alter the virulence and toxicity of L.
monocytogenes in vivo. A recombinant strain was generated that expressed a surface-associated LLO (sLLO)
variant secreted at 40-fold-lower levels than the wild type. In culture, the sLLO strain grew in macrophages,
translocated to the cytosol, and induced cell death. However, the sLLO strain showed decreased infectivity,
reduced lymphocyte apoptosis, and decreased virulence despite a normal in vitro phenotype. Thus, the topology
of LLO in L. monocytogenes was a factor in the pathogenesis of the infection and points to a role of LLO
secretion during in vivo infection. The sLLO strain was cleared by severe combined immunodeficient (SCID)
mice. Despite the attenuation of virulence, the sLLO strain was immunogenic and capable of eliciting protec-
tive T-cell responses.
Listeria monocytogenes is a gram-positive facultative intra-
cellular pathogen extensively used to understand host-patho-
gen interactions (44, 51, 53). It expresses the highly conserved
pore-forming toxin listeriolysin O (LLO), a member of a large
family of cholesterol-dependent cytolysins found in many im-
portant pathogens (11, 33, 50). LLO is required for L. mono-
cytogenes virulence both in vivo and vitro. L. monocytogenes
genetically deficient in LLO (hly) is incapable of any growth
in vivo or inducing protective immunity except at extremely
high infectious doses (27). This finding supports the relation-
ship between virulence and development of strong protective
immunity.
The effect of LLO on cells is multifaceted. It induces calcium
fluxes at the cell surface (16, 46), cytokine production by
splenocytes (40), apoptosis of dendritic cells and T lympho-
cytes (8, 26), and Toll-like receptor 4 signaling (43). LLO is
also a source of T-cell epitopes of L. monocytogenes in multiple
major histocompatibility complex (MHC) haplotypes (22, 52).
Most studies on LLO have focused on its ability to perforate
the phagolysosome at acidic pH, which allows L. monocyto-
genes to enter the cytosol of the infected phagocytic cell (24,
45). The hly strain does not cross from the phagosome to the
cytosol and is effectively killed (20, 45). L. monocytogenes con-
structed to express variable levels of LLO protein in vitro has
shown a dose threshold that must be reached for entry into the
cytosol (14). There is recent work that suggests that low levels
of LLO secretion can lead to maintenance of L. monocytogenes
in vacuoles, suggesting a possible mechanism for granuloma
formation and persistent infection in immunocompromised
strains of mice (6).
During infection with L. monocytogenes, there is a phase of
lymphocyte apoptosis in the spleen that peaks at the second
day of the infection (30, 34). Apoptosis is dependent on the
level of infection with L. monocytogenes. High doses of LLO-
deficient or heat-killed L. monocytogenes do not induce the
lesions, demonstrating that live, virulent infection is required
for their development. Induction of lymphocyte apoptosis is
immunomodulatory and a major determinant in the virulence
of L. monocytogenes infection (11). For example, mice deficient
in type I interferon (IFN) receptor signaling are more resistant
to listeriosis and have decreased levels of lymphocyte and
macrophage apoptosis (2, 10, 41). Tumor necrosis factor
(TNF)-related apoptosis-inducing ligand/ (TRAIL) mice
are also more resistant to infection and have less apoptosis
(54), while liver X receptor/ (LXR) mice have increased
macrophage apoptosis and are more susceptible to listeriosis
(32). And pointedly, mice deficient in lymphocytes have no
detectable splenic apoptosis and are more resistant early after
infection than conventional mice (3, 9).
Our interpretation on the pathogenesis of the lesions is that
LLO released extracellularly during the strong exponential
phase of growth is central for their development. Treatment of
cultured T cells at neutral pH with sublytic nanomolar and
subnanomolar doses of LLO can induce apoptosis (8). The
apoptosis induced by LLO on activated T cells is highly de-
pendent on granzyme expression within the affected cell (12).
Nonactivated lymphocytes can be sensitized to the apoptotic
effect of LLO by treatment with type I IFN (10).
To examine the possible role of LLO as an extracellular
protein, we engineered a recombinant strain of L. monocyto-
genes in which the LLO protein is covalently linked to the
bacterial cell wall (surface-associated LLO [sLLO]). The sLLO
strain expresses wild-type levels of bacterially associated LLO
but secretes 40-fold less total protein. The growth, pathoge-
nicity, and inflammatory properties of the sLLO strain are
severely attenuated in vivo. Importantly, there is reduced apop-
tosis in the infectious foci following infection with the sLLO
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mutant. This strain is also capable of eliciting memory T-cell
responses and protective immunity.
MATERIALS AND METHODS
Generation of sLLO-expressing L. monocytogenes. Figure 1A shows a sche-
matic of the strategy employed to generate sLLO (17, 48). A fragment of the
LLO gene (hly) was isolated from the EGD strain genome by PCR with primers
5-GTCGACCTAAATCAAACGTTAACAACGCAG-3 and 5-GGATCCTTC
GATTGGATTATCTAC-3. Primers were designed to amplify a region span-
ning the last 1,067 bp of the LLO coding region and incorporate a 5 SalI site and
a 3 BamHI site for subsequent cloning. The fragment of LLO was cloned into
the gram-positive shuttle vector pKSV7 by directional cloning using SalI and
BamHI digests of the vector and insert (48). This fragment of LLO served as the
“5 Arm” for homologous recombination and removed the stop codon of the LLO
gene. Next, the region of internalin A (inlA) known to encode the cell wall associ-
ation motif (LPXTG) was amplified by PCR with primers 5-TTAAGGATCCCA
CCACCACCACCACCACCTCCCTACAACTGGCGATAGCG-3 and 5-AATT
GGATCCGCGGCCGCTTATTATTTACTAGCACGTGCTTTTTTAGTAAGA
GCC-3 from the EGD genome. Both primers contained a BamHI site, the 3
primer contained a NotI site, and the 5 primer contained a hexahistidine linker that
was included in the recombinant LLO construct previously described (21, 24). This
fragment was cloned into pKSV7 containing the 5 Arm fragment to yield LLO
followed by a hexahistidine linker and finally the internalin A sorting sequence
with a stop codon, 5Arm/Linker/LPXTG. The final step was to PCR amplify the
500 bp immediately 3 of the LLO stop codon (3 Arm) with primers 5-AATT
GCGGCCGCTTGTAAAAGTAATAAAAAATTAAG-3 and 5-AATTGCGG
CCGCTTGTAAAAGTAATAAAAAATTAAG-3. This fragment was cloned
after the LPXTG sequence. The final construct was grown up in TOP10 cells,
and the plasmid was isolated. Transformation and homologous recombination
were carried out into the L. monocytogenes strain EGD using the penicillin G
transformation protocol described previously (17).
Genotypic characterization of the L. monocytogenes sLLO mutant. Transfor-
mants were first screened by PCR using a primer specific for the 5 end of the
LLO gene (5-GTCCTCTCGTAAAAGCGAATTCG-3) and a 3 primer spe-
cific for the LPXTG sequence of inlA (5-AATTGCGGCCGCTTGTAAAAGT
AATAAAAAATTAAG-3). Putative recombinants were further screened by
Southern analysis. Bacteria were subcloned by streaking out on brain heart
infusion (BHI)-agar plates until the Southern blot and PCR were both positive
for 100% of the bacteria after subcloning. For Southern analysis, genomic bac-
terial DNA was cut with BamHI, resolved on a 1% agarose gel, transferred to a
nylon membrane, and probed against the 5 end of the coding region of LLO.
The wild-type band was expected to migrate at 3,454 bp and the properly
targeted mutant at 2,312 bp. The Southern blot was also performed with BsaAI
for further confirmation. BamHI and BsaAI were selected because novel sites of
each were introduced into the LLO locus by the manipulations used to generate
the recombinant sLLO strain. Individual clones were screened and subcloned
until homogeneous by both Southern analysis and PCR. Stability of the mutation
was verified after infection in both wild-type and SCID mice followed by screen-
ing of 6 to 10 colonies per infected mouse.
Immunoblot analysis. Bacterial strain EGD and the hly (LLO-deficient) and
sLLO strains were grown in standing BHI culture overnight at 37°C. Overnight
cultures were used to inoculate shaking cultures of BHI. Bacteria were grown at
37°C until mid-log phase (optical density at 560 nm [OD560] of 0.8 to 1.0) and
centrifuged at a relative centrifugal force (RCF) of 8,000, and the supernatants
were collected. Culture supernatant, cell wall, and protoplasts were fractionated
and precipitated as described previously with lysozyme treatment for 1 h instead
of endolysin treatment (49). Protein was transferred onto polyvinylidene diflu-
oride (PVDF) membranes, and LLO was detected with the anti-LLO monoclo-
nal antibody A4-8 (37). A Coomassie blue gel was run in parallel to confirm
equivalent loading of lanes.
RBC lysis assays. Bacteria were grown as described in the previous section.
Bacteria were spun down at an RCF of 8,000 and washed twice in a buffer
containing phosphate-buffered saline (PBS [pH 6.0]), 0.1% bovine serum albu-
min (BSA), and 0.01 M dithiothreitol. Twofold dilutions of the supernatants
were combined with human red blood cells (RBC) and incubated for 1 h at 37°C.
Human RBC were isolated from various normal patients and washed three times
in PBS (pH 6.0)–0.1% BSA. The final assay conditions were 1 PBS (pH 6.0),
0.1% BSA, 0.005 M dithiothreitol, and 3% RBC and dilution of culture super-
natant. After incubation, cells were spun out at an RCF of 600 to remove unlysed
RBC, supernatants were collected, and OD570 was determined for the superna-
tant of each sample.
Mice and L. monocytogenes infection. C.B-17 and C.B-17 SCID mice were bred
and maintained at Washington University School of Medicine under specific-
pathogen-free conditions. All protocols were performed in accordance with the
guidelines of the Division of Comparative Medicine of Washington University
School of Medicine. Mice of both genders were infected at 8 to 12 weeks of age.
Bacteria were stored as frozen glycerol stocks, thawed, and diluted into pyrogen-
free saline prior to infection. All mice were infected intraperitoneally with a final
volume of 0.5 ml. All antibodies used in this study were generated, purified, and
used as described previously (18). Hematoxylin and eosin staining and terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick-end labeling (TUNEL)
staining were performed as described previously (34). L. monocytogenes was
detected in tissue sections by immunofluorescence using a 1:200 dilution of
rabbit polyclonal anti-Listeria antibody (BD Pharmingen, Valencia, CA) fol-
lowed by detection with a 1:200 dilution of goat anti-rabbit Atto 488 (Sigma, St.
Louis, MO). Mann-Whitney U test was used for all statistical analyses.
In vitro assays. Coverslip assays for growth and for determination of escape
into the cytosol were performed as described previously (19). Plaque assays were
performed as described previously with slight modifications (4, 31). Plaque assays
were carried out in six-well plates and overlaid with methylcellulose instead of
agarose. L929 cells were used to form the monolayers for plaque assays. Enzyme-
linked immunospot (ELISPOT) assays for gamma IFN (IFN-) and interleu-
kin-2 (IL-2) were performed with matched ELISPOT antibody sets (BD Phar-
mingen) and used according to the manufacturer’s instructions. Cytokines from
culture supernatants or sera were determined by cytometric bead array assay
(BD Pharmingen) using the manufacturer’s instructions. Type I IFN in the
spleen was determined by enzyme-linked immunosorbent assay (PBL Laborato-
ries). Relative IFN- induction was determined by quantitative reverse transcrip-
tion-PCR (qRT-PCR) using SYBR green (Bio-Rad iCycler) and cycle threshold
(Ct) analysis using hypoxanthine phosphoribosyltransferase (HPRT) as the
housekeeping control.
RESULTS
Generation and properties of a strain of L. monocytogenes
that expressed LLO associated with its cell wall. We hypoth-
esized that LLO released into the extracellular milieu was
responsible for the extensive lymphocyte apoptosis during in-
fection. By limiting LLO secretion, we would reduce apoptosis
and attenuate L. monocytogenes virulence. Our goal was to
limit the amount of LLO released into the cytosol and extra-
cellular space while still allowing the bacteria to escape the
phagosome of infected macrophages. To this end, a mutant
(sLLO) L. monocytogenes strain was generated that expressed
LLO covalently associated with the cell wall via the bacterial
sortase. One major mechanism gram-positive bacteria use to
associate their proteins with the cell wall is sortase-mediated
covalent binding to the peptidoglycan (38, 49). The minimal
sequence required for sortase-mediated association of the
L. monocytogenes protein internalin A has been well studied,
so our strategy involved adding the inlA gene sorting se-
quence to the 3 end of LLO. The final DNA construct (Fig.
1A) was generated and transformed into the wild-type EGD
strain of L. monocytogenes. Bacterial clones were screened
by PCR and Southern blotting to identify successful recom-
binants (Fig. 1B).
Our initial examination of the sLLO strain involved growth
in shaking culture at 37°C to determine rates of growth. Wild-
type EGD and the sLLO mutant grew at the same rate in
multiple experiments, both reaching an OD600 reading of mid-
log growth (0.8 to 1.2) 3 to 4 h after the beginning of culture in
BHI. Both strains also reached the same level of absorbance
(OD600 of 1.2 to 1.5) following an overnight standing culture in
BHI. Therefore, the introduction of a mutation into the LLO
gene did not adversely affect the growth of the sLLO mutant
compared to its wild-type counterpart.
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FIG. 1. Genotype and in vitro phenotype of the sLLO mutant of L. monocytogenes. (A) Genomic construct of LLO bearing a hexahistidine
linker and the LPXTG cell wall targeting motif of internalin A. (B) Southern analysis of the wild-type (1) and sLLO (2) strains on BamHI-digested
genomic DNA with a probe directed against LLO. The wild-type sequence migrated at 3,454 bp, and the mutant variant migrated at 2,312 bp.
(C) Immunoblot analysis of bacterially associated LLO. Mid-log culture supernatants (media), cell wall fraction (cell wall), or protoplasts were
isolated as described in Materials and Methods. LLO was detected by immunoblotting with an LLO-specific monoclonal antibody (A4-8).
(D) Culture supernatants of the mid-log-cultured sLLO, EJL-1, and EGD strains were tested for hemolytic activity on human RBC. (E) Mice were
infected with 106 EGD or sLLO strain cells, and spleens were homogenized and plated on BHI. Single colonies were picked and grown overnight
in standing BHI culture at 37°C. Numbers 1 to 6 in panel E represent individual colonies of the sLLO strain. Supernatants were serially diluted,
and hemolytic activity was determined by RBC lysis assay. (F) PEC were infected with equivalent doses of the EGD, EJL-1, or sLLO strain, and
at the indicated times, cells were lysed and total bacterial number was determined by titration on BHI agar plates. Points represent the mean 
standard error for triplicate wells. (G) PEC (2.5  105) were infected with equivalent numbers of EGD or sLLO strain cells (MOI of 1), and at
the indicated times (hours), the cells were fixed and stained for L. monocytogenes and phalloidin. The percentage of cytosolic bacteria was
determined by counting phalloidin-positive L. monocytogenes cells and dividing it by the total number of bacteria. Each bar represents the
percentage determined from counting four to six microscopic fields from two independent experiments. The total number of bacteria counted was
between 350 and 800 per bar. There was no statistical difference between the EGD and sLLO groups (Mann-Whitney U test).




arch 26, 2014 by W







Next, we wanted to determine if the recombinant LLO was
covalently associated with the cell wall. Bacterial culture me-
dia, cell wall fractions, and protoplast fractions of EGD and
the sLLO mutant were prepared, and LLO in each fraction was
detected by immunoblot analysis. Figure 1C shows an immu-
noblot of the three fractions. EGD secreted more LLO into
culture media than the sLLO strain. In contrast, the sLLO
strain contained more cell wall-associated LLO than EGD.
Both bacteria contained comparable levels of protoplast-asso-
ciated LLO. We also performed all three isolations with the
LLO-deficient strain EJL-1 and did not detect any protein by
immunoblotting (data not shown). We conclude from this that
the sLLO strain expresses covalently attached LLO on its cell
wall and secretes qualitatively less LLO into culture media
than EGD.
Since it is difficult to quantify the amount of LLO being
secreted by either EGD or the sLLO strain by immunoblotting,
we used RBC hemolysis to determine the amount of functional
LLO that was secreted. Human RBC were treated with culture
supernatant from mid-log-phase cultures of the EGD or sLLO
strain. The sLLO strain supernatant showed an 	40-fold re-
duced lytic activity compared to the EGD supernatant (Fig.
1D), a finding consistent with the immunoblot analysis shown
in Fig. 1C. Additionally, the hemolytic activity could be neu-
tralized by addition of 1 mg/ml anti-LLO A4-8 (data not
shown).
To demonstrate that the sLLO genotype was stable, mice
were infected with 104 sLLO mutant cells, and bacterial colo-
nies were isolated from spleens by standard techniques. Con-
sistent with the results shown above, six out of six sLLO iso-
lates had diminished or no lytic activity in culture supernatants
(Fig. 1E). The presence of the sLLO mutation was also con-
firmed by PCR and Southern blotting (data not shown). Thus,
the sLLO mutant is a stable strain of L. monocytogenes that
sheds 	40-fold less than the wild-type strain.
LLO allows egress of L. monocytogenes from the phagosome
to the cytosol and cell-to-cell migration of bacteria. The han-
dling of the EGD and sLLO strains by macrophages was tested
to determine if there was impairment in the in vitro growth of
the sLLO strain (4, 19). Figure 1F shows a time course of
infection of peritoneal exudate cells (PEC) with the sLLO,
EGD, and hly strains. Both the EGD and sLLO strains
showed the typical growth pattern, with an initial reduction
followed by progressive growth, the latter an indication that
the bacteria had reached the cytosol. The hly strain did not
grow in macrophages. We determined that the EGD and sLLO
strains entered into the cytosol at the same rate and in com-
parable numbers by staining infected cells with phalloidin and
anti-L. monocytogenes antibody (Fig. 1G). Colocalization of
phalloidin and bacteria is an indication of the actin polymer-
ization that occurs only in the cytosol. Combined, these results
show that the sLLO mutant strain is capable of normal growth
and phagosomal escape in infected macrophages.
An additional function of LLO is to enhance bacterial
spread from one infected cell to an adjacent cell (21). In the
cell-to-cell spread assay, L. monocytogenes either transits from
one cell to the next or is killed by gentamicin present in the
culture. Both the EGD and the sLLO mutant strains formed
equivalent numbers of plaques of approximately the same size.
It was previously shown that LLO-deficient strains form small
plaques, which was not the case for the sLLO mutant (4). The
sLLO or the small amount of LLO shed by the sLLO mutant
was sufficient to permit cell-to-cell spread. The terminal stage
of a productive infection with L. monocytogenes is the death of
the infected cell. EGD and sLLO mutant cells that gained
access to the cytosol were toxic to the infected cell. We de-
tected nuclear condensation, cell detachment, and propidium
iodide staining in macrophages and PEC cells infected with
sLLO mutant and EGD cells for more than 16 h (data not
shown). Therefore, sLLO mutant cells can gain access to the
cytosol and grow well, eventually compromising the integrity of
the infected phagocytic cell.
Comparison of EGD versus sLLO mutant infection in
C.B-17 mice. The infectivity and virulence of EGD and sLLO
in vivo were tested in wild-type C.B-17 mice. The 50% lethal
dose (LD50) for EGD in C.B-17 mice was 10
5 CFU, and that
for the sLLO mutant was 
5  107 for sLLO (Fig. 2A and B).
Figure 2C to F show a comparison of EGD against the sLLO
strain 2 days after infection. C.B-17 mice infected with 104
CFU of EGD had the same colony counts as mice infected with
107 CFU of the sLLO strain (Fig. 2C and D). Infection with 105
CFU of EGD gave the same colony counts as infection with
108 CFU of the sLLO strain (Fig. 2E and F). We concluded
that the sLLO strain had a 1,000-fold virulence attenuation
compared to EGD. Similar differences in colony counts were
seen at day 4 postinfection (data not shown).
In order to determine when the sLLO growth defect oc-
curred, mice were infected and colony counts determined dur-
ing the first few hours following infection (Fig. 2G). C.B-17
mice were infected intravenously (i.v.), and colony counts were
determined at 0.5, 1, 2, 4, 6, and 24 h postinfection. The initial
level of infectivity with the sLLO strain was reduced compared
with that of the EGD strain: a statistically significant difference
was found within the first 30 min following infection (P 
0.0037 at 0.5 h by Mann-Whitney U test). During the first hour,
both bacteria showed no change in colony counts. However,
after 4 h, the sLLO strain decreased in number. Other studies
have shown that L. monocytogenes is initially trapped in the
marginal zone of the spleen, where it resides during the first 4
to 6 h. At the 4- to 6-h time period, L. monocytogenes is
transported to the periarteriolar lymphoid sheaths (PALS),
where it grows exponentially (1, 29, 36). This migration is
dependent on LLO expression, because the hly strain does
not enter into PALS. Both the sLLO mutant and EGD grew
exponentially after 4 to 6 h of infection, but the sLLO strain
never reached the same rate of growth as EGD: compare the
4-, 8-, and 24-h time points in Fig. 2G. Figure 2H shows that
the sLLO strain can grow progressively in both the spleens and
livers, reaching peak levels at the second day of infection. The
sLLO strain was rapidly cleared from the spleen after the 4th
day of infection. In additional experiments, both the sLLO and
EGD strains were cleared from both livers and spleens by day
8 postinfection (data not shown).
LLO is an important component of the inflammation in-
duced by L. monocytogenes infection. We infected C.B-17 mice
with EGD and sLLO mutant cells and determined the level of
serum cytokines at day 3 of the infection. Infection of mice
with L. monocytogenes EGD induced high levels of TNF-,
monocyte chemoattractant protein 1 (MCP-1), and IL-6 and
modest levels of IFN- that were compatible with levels seen
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by our laboratory and others (Fig. 3A to D). Infection with the
sLLO strain did not lead to robust inflammatory cytokine pro-
duction at lower doses of infection. Consistent with colony
count information, we detected comparable levels of inflam-
matory cytokine induction in vivo at a 3-log-higher input in-
fection of the sLLO strain (Fig. 3A to D).
The reduction in cytokine production in vivo was not due to
an inability of the sLLO strain to induce macrophage cytokine
production. Peritoneal macrophages were infected with the
sLLO strain or EGD, and then TNF-, MCP-1, and IL-6 were
measured at 24 h postinfection (Fig. 3E to G). We found
similar levels of all three cytokines for the sLLO and EGD
strains. This reinforces the results seen earlier, where the phe-
notype of the sLLO strain in vitro is the same as that of EGD
despite a dramatic difference in vivo. We also measured the
induction of IFN- mRNA by qRT-PCR. Peritoneal macro-
phages induced IFN- 
10,000-fold 6 h after infection with
either EGD or the sLLO strain (multiplicity of infection [MOI]
of 10) or treatment with poly(I  C) (100 ng/ml) (Fig. 3H). We
conclude that sLLO has reduced inflammatory capacity in vivo
FIG. 2. Infection of wild-type mice with either the sLLO or EGD strain. (A and B) C.B-17 mice were infected with the indicated doses of the
EGD or sLLO strain and monitored for survival. (B) We saw no lethality in the sLLO strain at 106, 107, or 5  107, so the lines overlap. (C to
F) C.B-17 mice were infected with the indicated doses of either the EGD (C and E) or sLLO (D and F) strain, and bacterial burden in the spleen
and liver was determined at day 2 postinfection. (G) C.B-17 mice were infected with 107 EGD or sLLO strain cells, and colony counts per spleen
were determined at the indicated hours postinfection. Each bar represents the mean  the standard error of the mean of at least eight mice per
group. (H) C.B-17 mice were infected with 5  107 CFU of the sLLO strain, and bacterial titers were determined at days 1, 2, and 4 postinfection.
Points represent the mean  standard error of the mean of at least four mice per group.
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which correlates with infectious dose, despite normal induction
of cytokines in infected cultured cells.
In light of the suggested role of LLO in bacterial migration
into the PALS, the localization of EGD and sLLO mutant cells
in the spleens of infected C.B-17 mice was compared by im-
munofluorescence. As expected, 2 h postinfection, both EGD
and sLLO mutant cells localized to the marginal zone (Fig. 4).
By 24 h postinfection, both strains were found in the PALS,
although fewer sLLO strain than EGD bacteria were detected.
Therefore, the sLLO strain was able to access PALS.
Comparison of EGD versus sLLO strain infection in SCID
mice. We initially hypothesized that secreted LLO was respon-
sible for lymphocyte apoptosis seen after infection of wild-type
mice (8). If the decreased virulence of the sLLO strain was
entirely caused by reduction of lymphocyte apoptosis following
infection, we would expect that SCID mice would not show as
profound a difference in control of the sLLO strain versus
EGD as the wild-type mice.
C.B-17 SCID mice were infected with both strains over a
range of doses. SCID mice were quite resistant to both bacte-
rial strains (Fig. 5A and B), consistent with previous observa-
tions from our laboratory (3, 9). Despite the absence of lym-
phocytes, the sLLO strain was still highly attenuated. For
example, at 70 days postinfection, a 106-CFU inoculum of
EGD resulted in 75% lethality compared to 0% lethality when
mice were infected with the sLLO strain. At the 106 infectious
dose, 	104 colony counts for the EGD strain were found 4
days later (Fig. 5C and D) but bacteria were not recovered
from the sLLO strain-infected SCID mice. Similar differences
were also observed at higher infectious doses.
Due to the absence of T cells, wild-type L. monocytogenes
establishes a chronic infection in SCID mice (5). We were able
to recover EGD but not sLLO strain cells from mouse spleens
and livers 14 days after infection (Fig. 5E and F). We were
unable to find a dose of the sLLO strain that established a
chronic infection: even though the sLLO strain was infectious
and virulent, it did not persist in SCID mice. At the very high
108-CFU dose, both strains killed the mice within the first 4 to
8 days of infection. The time course of bacterial burden in
SCID mice following infection with 108 CFU of the sLLO
strain is shown in Fig. 5G: there were high titers in both the
spleen and liver from days 2 to 6 postinfection. The sLLO
strain was difficult to detect by the 4th day of infection in SCID
mice, and in several experiments, we found no bacterial burden
at day 14 postinfection, a time at which the EGD strain is
found chronically infecting SCID mice.
Together, our data suggest that the sLLO strain is poorly
virulent in SCID mice at low doses, but once a threshold dose
is reached, it can grow vigorously and kill mice. At sublethal
doses, the sLLO strain was unable to establish the chronic
infection typically seen with sublethal infection with EGD.
Other features of the infection with the sLLO strain of L.
monocytogenes. Histological analysis of C.B-17 mice that had
equivalent EGD and sLLO strain burdens at day 2 postinfec-
tion showed infective foci in the PALS of the white pulp (Fig.
6A and B). When adjacent sections were stained by TUNEL,
lymphocyte apoptosis was detected with both strains (Fig. 6C
and D). However, the extent of the lesions was markedly re-
duced in sLLO strain-infected mice despite an equivalent bac-
terial burden. At sLLO strain infectious doses of 107 CFU,
few TUNEL-positive cells were found despite a measurable
bacterial burden in the spleen (Fig. 2D). In contrast, EGD-
infected mice with the same bacterial burden showed signifi-
cant TUNEL-positive lesions. The livers of mice infected with
FIG. 3. Inflammatory cytokine responses and T-cell responses following infection with the sLLO or EGD strain. (A to D) Mice were either
uninfected or infected with the indicated doses of the EGD or sLLO strain for 3 days. Spleens were isolated from mice and tested by cytometric
bead array for TNF- (A), MCP-1 (B), IL-6 (C), or IFN- (D). (E to G) C.B-17 PEC were left untreated (0), infected with an MOI of 1 or 10
of either the sLLO or EGD strain for 24 h, or treated with 10 ng/ml lipopolysaccharide and 100 ng/ml poly(I  C), and then culture supernatants
were assayed for either TNF- (E), MCP-1 (F), or IL-6 (G) content by CBA. Bars represent the mean  standard error for either four to six mice
or three culture supernatants per group. Asterisks indicate assays in which the maximal limit of detection was reached. The Mann-Whitney U test
did not find a statistical difference between any of the MOI 1 or 10 cytokine responses between the EGD and sLLO strains. (H) A total of 106
C.B-17 PEC were infected with the EGD or sLLO strain at an MOI of 10 or 100 ng/ml poly(I  C), and after 6 h, total RNA was isolated, treated
with DNase I, and reverse transcribed, and qRT-PCR was performed using SYBR green with an internal fluorescein loading control (iCycler, IQ
master mix; Bio-Rad). Induction (fold) of IFN- mRNA was determined by Ct calculation with HPRT as the housekeeping control. Bars
represent the mean of independent samples assayed in duplicate.
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either bacterial strain had comparable pathology and at 48 h
showed the typical microabscesses.
Neutralization of LLO using the monoclonal antibody A4-8
renders wild-type L. monocytogenes avirulent (18, 19). Figure
7A shows that A4-8 inhibits the in vivo growth of the sLLO
strain, indicating that the LLO produced by both strains con-
tributed to their infectivity. Histological sections of spleens
from the same mice in Fig. 7A were analyzed for the extent of
apoptosis found in their white pulp profiles. Mice that received
control GIR.208 antibodies had 30% and 26% of their white
pulp profiles containing either large or medium apoptotic le-
sions. In contrast, after A4-8 treatment, 6% and 15% of white
pulp profiles contained large and medium apoptotic lesions,
respectively. In the GIR.208 group, 25% of the white pulp
profiles contained no apoptotic lesions versus 57% for the
A4-8-treated group. Therefore, treatment with A4-8 reduced
the number and extent of apoptotic lesions following sLLO
strain infection by over 50%.
Depletion of neutrophils with the anti-GR1 antibody has a
profound effect on murine listeriosis (13, 47). Strains of L.
monocytogenes that express hypervirulent mutants of LLO are
presumed to be more sensitive to neutrophils and antibiotics
because they gain access to the extracellular milieu too quickly
(23). In order to rule out the possibility that the sLLO strain is
a hyperactive mutant in vivo, we depleted treated mice with the
neutrophil-depleting antibody RB6.8C5 prior to infection. Fig-
ure 7C and D show the effect of neutrophil depletion on
infection with the sLLO and EGD strains. Both strains of L.
monocytogenes were responsive to the effect of neutrophil de-
pletion, with about a 100-fold increase in colony counts in the
spleen and a 1,000-fold increase in colony counts in the liver.
Thus, the sLLO strain was as sensitive to neutrophil deletion as
the EGD strain. Based on this data, we concluded that the
LLO expressed by the sLLO strain is not attenuating infection
due to increased accessibility to the extracellular space.
T-cell response to the sLLO strain. We wanted to determine
if the sLLO strain, despite its dramatically reduced in vivo
virulence, could elicit T-cell responses. C.B-17 mice were in-
fected with 104 CFU of either the sLLO or EGD strain, and
the number of antigen-specific T cells was determined by
ELISPOT for IFN- or IL-2 (Fig. 8A and B). Three different
proteins were used as recall antigens: (i) whole LLO protein
with the W492A mutation to decrease bystander cell lysis (35);
(ii) the LLO peptide 188–201, which binds the MHC class II
molecule I-Ad (22); or (iii) the LLO 91–99 peptide, which
binds the MHC class I molecule H-2Kd (52). Both strong CD4
and CD8 T-cell responses were found from both the sLLO and
EGD strains after 1 week of infection. Against LLO protein
(the W492A mutant), there were 	1,700 IFN- and 	110
IL-2-producing T cells per million total spleen cells for EGD
and 	1,000 IFN- and 	60 IL-2-producing T cells per million
total spleen cells for the sLLO strain. Thus, the sLLO strain
elicited a strong T-cell response of comparable magnitude to
the wild-type EGD strain at infectious doses 104-fold lower
than its LD50. LLO alone did not cause proliferation of CD4

or CD8 cells isolated from immunized lymph nodes. In assays
involving purified CD4 or CD8 cells, exogenous irradiated
syngeneic spleen cells were used as the antigen-presenting
cells.
In order to demonstrate protective immunity, C.B-17 mice
were infected with either the sLLO or EGD strain at two
different doses (103 or 104 CFU/mouse). After 21 days, both
groups were challenged with 105 CFU of EGD (LD50), and
colony counts were determined at the 3rd day of infection.
Immunization with both strains led to decreased colony counts
in the spleen and liver compared to those in the unimmunized
control (Fig. 8C and D). The sLLO strain at the 104-CFU dose
conferred an 	100-fold protection, while the EGD strain was
more effective, about 1,000-fold. Even though the protection
FIG. 4. Localization of the sLLO and EGD strain cells in infected
spleens. Mice were either left uninfected or were infected with the
EGD or sLLO strain for the times indicated. For the 2-h infections,
mice received 108 CFU of either the EGD or sLLO strain. For the 24-h
infections, mice received 106 CFU of the EGD strain or 107 CFU of
the sLLO strain. Spleens were isolated from all mice, flash frozen,
sectioned, and stained against L. monocytogenes (green), CD19 (red),
or DAPI (4,6-diamidino-2-phenylindole; blue). The white insert box
in the left panels indicates the region shown on the corresponding right
panels. White bars represent 100 m. Fields are representative of at
least three mice per group.
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afforded by the sLLO strain is not a robust as that of EGD, it
is far better than that of the hly strain, where i.v. 109-CFU
infection is required to detect any protective immunity (27).
Additionally, we infected C.B-17 mice with 106 sLLO strain
CFU and then 28 days later rechallenged them with a 10
LD50 dose of EGD (10
6 CFU/mouse) and found that 7/8 mice
were protected from lethality. The mock-treated controls all
died following the infection (0/8 survival). Therefore, the
sLLO mutant can confer a survival advantage against a lethal
challenge with the wild-type strain. Even though there are
many variants of L. monocytogenes that have been used as good
vaccines (ActA and killed but metabolically active), this ap-
proach represents a new method for generating recombinant
bacteria that can be used as an immunogen (7, 25).
DISCUSSION
A genomic mutant of L. monocytogenes, the sLLO strain,
was generated that expressed LLO as a fusion protein with the
LPXTG cell wall-targeting motif of internalin A. The novel
FIG. 5. Infection of SCID mice with either the sLLO or EGD strain. (A and B) SCID mice were infected intraperitoneally with the indicated
doses and monitored for survival. (C and D) SCID mice were infected with the indicated doses of EGD or sLLO strain cells, and bacterial burden
was determined at day 4 postinfection. (E and F) SCID mice were infected with the indicated doses of EGD or sLLO strain cells, and bacterial
burden was determined at day 14 postinfection. (G) SCID mice were infected with 108 CFU of the sLLO strain intraperitoneally, and colony counts
were measured at the indicated days postinfection. Each point represents the CFU per organ for one mouse. Bars represent the mean for each
group.
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strain of L. monocytogenes had LLO anchored to its cell wall
and secreted about 40-fold less LLO into culture supernatants.
In vitro examination demonstrated that the sLLO mutant be-
haved like the wild-type strain with respects to all known in
vitro functions of LLO, including hemolysis, phagosomal es-
cape, cell-to-cell spread, and cytotoxicity. The in vitro behavior
of the sLLO strain was confounding, because it was markedly
attenuated in virulence (about a 3-log difference) compared to
the wild type. One thousand-fold more bacteria were required
to get equivalent colony counts over a 3-log range of infective
doses, and this translated into increased survival after infection
with the sLLO strain.
At face value, the differences between the behavior of the
sLLO and EGD strains suggest a role for high levels of secre-
tions of LLO in virulence that cannot be ascribed to its known
biology within the infected cell. LLO may be released from L.
monocytogenes during its short extracellular stage before up-
take by macrophages or after its uptake, when inflammation
sets in and cell death takes place. Structural studies during this
stage show occasional profiles of free L. monocytogenes cells
within cellular debris (34). Once LLO is released from the
phagocytes that first capture the bacteria, it may drive inflam-
mation and cytotoxicity that is detrimental to the host. One
possible hypothesis is that more LLO is being shed in vacuoles
than in broth culture, thereby allowing the sLLO strain to grow
in vitro. Even if this is occurring, it cannot account for the
profound difference in virulence observed in vivo. We know
that within the first few hours L. monocytogenes is localized to
the marginal zone, where it resides in phagocytic macrophages
(Fig. 4D) (1, 36). Even at these early time points, where the
sLLO strain resides in macrophages in vivo, it is incapable of
growth, and in fact decays over the first 4 h following infection
(Fig. 2G).
The sLLO strain allows us to speculate on the biology of this
important experimental model of bacterial infection. In partic-
ular, three findings merit discussion. The first finding relates to
the pronounced lymphocyte apoptosis which translates into a
brief period of susceptibility to the infection. At infective doses
that yielded the same bacterial burden with the sLLO and
EGD strains, we found both strains localized in the PALS.
However, the extent of lymphocyte apoptosis was diminished
in the sLLO strain. This occurred both within individual PALS
and in the percentage of affected PALS profiles per infected
spleen. We infer that EGD was more apoptogenic because it
released LLO, most likely at a time when there were few
profiles of extracellular LLO in the infective foci (34). This
result supports our original hypothesis that LLO was one caus-
ative factor of lymphocyte apoptosis and subsequent immuno-
suppression after infection of wild-type mice (8, 9). One should
note that monoclonal antibodies to LLO decreased lympho-
cyte apoptosis, which can now be explained by neutralization of
the extracellular cytotoxic LLO (18).
Second, despite the findings in vitro, tissue phagocytes con-
trolled the growth of the sLLO strain very effectively. This was
particularly evident in the SCID mouse, where only very high
FIG. 6. Histological analysis of sLLO strain-infected mice. C.B-17
mice were infected with 105 CFU of EGD (A and C) or 108 CFU of the
sLLO strain (B and D). At day 2 postinfection, mice were sacrificed
and the spleens were removed, fixed in formalin, sectioned, and
stained by hematoxylin and eosin (A and B) or TUNEL (C and D) as
described in Materials and Methods. All panels are at a magnification
of 400.
FIG. 7. Characterization of sLLO strain infection in C.B-17 mice. (A and B) C.B-17 mice were treated with 1 mg of either the LLO-neutralizing
antibody A4-8 or the GIR.208 control antibody, and 24 h later, they were infected with 108 CFU of the sLLO strain. (A) Mice were sacrificed at
day 2 postinfection, and colony counts were determined. (B) Histology from the mice was scored for extent of apoptosis. Lesions were classified
by size from negative (neg; negative/no apoptosis) through low (small apoptotic lesions; 25% white pulp profile apoptotic), medium (med;
medium apoptotic lesions, 25 to50% white pulp profile apoptotic), and high (hi; large apoptotic lesions; 
75% white pulp profile apoptotic). The
data show the percentage of white pulp profiles from each mouse that fit each of the four categories. Bars are the mean  standard error of the
mean from four mice per group. (C and D) C.B-17 mice were treated with 250 g of RB6-8C5 or rat immunoglobulin G (IgG) at days 3 and
1. At day 0, mice were infected with either 104 CFU of EGD or 107 CFU of the sLLO strain. At day 3, mice were sacrificed and colony counts
were determined. Points represent individual titers per mouse organ. Bars are the mean  standard error for two independent experiments with
three or four mice per group.
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doses were infective. The results following infection of SCID
mice with 108 sLLO strain cells suggest that there was an initial
infectious threshold that must be crossed but that required
large amounts of secreted LLO. Once this threshold was
crossed, the bacteria could grow well in tissue and caused the
death of mice. The infection with SCID mice also suggests that
lymphocyte apoptosis alone could not explain all of the limited
virulence of the sLLO strain. There was no detectable lympho-
cyte apoptosis in the SCID mice: in fact, we saw no increase in
TUNEL-positive cells in the spleen following infection of
SCID mice with EGD (9).
We hypothesize that the control of sLLO strain growth by
tissue phagocytes is also exerted in normal mice by resident
macrophages, represented by the marginal zone macro-
phages in the spleen. What this apparent control means—
whether it results from a microbicidal effect of the marginal
zone macrophages or differences in the dynamics of cells
entering and leaving—is not clear. What was evident was the
lack of growth of EGD and a clear decrease in the sLLO
strain during the early colonization of the marginal zone. As
others have indicated, L. monocytogenes must be translo-
cated to the PALS, where it can grow exponentially (1, 36,
39). We have attempted to isolate the marginal zone mac-
rophages to determine if they are more bactericidal than
other phagocytic populations, but have been unable to iso-
late a splenic population consistent with the phenotype de-
tected by tissue staining.
A third and important finding is that the sLLO mutant
elicited a memory response that allowed for protection
against infection from wild-type L. monocytogenes. These
findings make the sLLO strain a good vector for immuniza-
tion against L. monocytogenes or heterologous antigens. L.
monocytogenes has been an effective vector for vaccine de-
velopment requiring the expression of LLO (15, 27, 28, 42).
We do not know another immunogenic strain of L. mono-
cytogenes that is cleared by SCID/RAG/ mice. Our own
experiments have shown that that the ActA-deficient strain
chronically infects RAG/ mice; therefore, it is not as safe
as the sLLO strain in immunocompromised settings (J. Car-
rero and E. Unanue, unpublished observations). Given the
importance of LLO and other cholesterol-dependent cytol-
ysins in the virulence of a wide range of gram-positive bac-
teria, these findings merit careful scrutiny, not only for the
development of better vaccines, but also to better under-
stand the role of pore-forming bacterial toxins in virulence
and immunogenicity during live infection.
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